Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 20/20 | 0.72 |
| ▸ | OPRL1 | P41146 | 19/20 | 0.72 |
| ▸ | OPRK1 | P41145 | 12/20 | 0.72 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18920990 | 1.00 | OPRM1 (0.72) | OPRM1OPRL1OPRK1OPRD1KCNH2 | |
| SCHEMBL23034730 | 1.00 | OPRM1 (0.72) | OPRM1OPRL1OPRK1OPRD1KCNH2 | |
| SCHEMBL20230143 | 1.00 | OPRM1 (0.72) | OPRM1OPRL1OPRK1OPRD1KCNH2 | |
| SCHEMBL18920994 | 1.00 | OPRM1 (0.72) | OPRM1OPRL1OPRK1OPRD1KCNH2 | |
| SCHEMBL29556487 | 0.90 | OPRL1 (0.73) | OPRM1OPRL1OPRK1OPRD1KCNH2 | |
| SCHEMBL20230112 | 0.90 | OPRM1 (0.76) | OPRM1OPRL1OPRK1OPRD1KCNH2 | |
| SCHEMBL20213000 | 0.90 | OPRM1 (0.76) | OPRM1OPRL1OPRK1OPRD1KCNH2 | |
| SCHEMBL20546748 | 0.90 | OPRM1 (0.73) | OPRM1OPRL1OPRK1OPRD1KCNH2 | |
| SCHEMBL20212997 | 0.90 | OPRM1 (0.76) | OPRM1OPRL1OPRK1OPRD1KCNH2 | |
| SCHEMBL23977722 | 0.90 | OPRL1 (0.73) | OPRM1OPRL1OPRK1OPRD1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49825-E1 | Piperidinyl nociceptin receptor compounds | ASTRAEA THERAPEUTICS, LLC (US) | 2024-02-06 | — | — | US | disclosed |
| US-10829471-B2 | Piperidinyl nociceptin receptor compounds | ASTRAEA THERAPEUTICS, LLC | 2020-11-10 | — | — | US | disclosed |
| US-20190300500-A1 | PIPERIDINYL NOCICEPTIN RECEPTOR COMPOUNDS | ASTRAEA THERAPEUTICS, LLC | 2019-10-03 | — | — | US | disclosed |
| US-10358432-B2 | Piperdinyl nociceptin receptor compounds | ASTRAEA THERAPEUTICS, LLC (US) | 2019-07-23 | — | — | US | disclosed |
| US-20180312486-A1 | PIPERDINYL NOCICEPTIN RECEPTOR COMPOUNDS | ASTRAEA THERAPEUTICS, LLC | 2018-11-01 | — | — | US | disclosed |
| US-10112924-B2 | Piperdinyl nociceptin receptor compounds | Astraea Therapeutics, Inc. (US) | 2018-10-30 | — | — | US | disclosed |
| US-20180155314-A1 | PIPERDINYL NOCICEPTIN RECEPTOR COMPOUNDS | ASTRAEA THERAPEUTICS, LLC | 2018-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10112924-B2 | Piperdinyl nociceptin receptor compounds | OPRL1, OPRK1, OPRD1 | OPRM1 4/4885OPRL1 1/4885OPRK1 2/4885 |
| US-10829471-B2 | Piperidinyl nociceptin receptor compounds | OPRL1, OPRK1, OPRM1 | OPRM1 3/4885OPRL1 1/4885OPRK1 2/4885 |
| US-20180312486-A1 | PIPERDINYL NOCICEPTIN RECEPTOR COMPOUNDS | OPRL1, OPRK1, OPRD1 | OPRM1 4/4885OPRL1 1/4885OPRK1 2/4885 |
| US-10358432-B2 | Piperdinyl nociceptin receptor compounds | OPRL1, OPRK1, OPRD1 | OPRM1 4/4885OPRL1 1/4885OPRK1 2/4885 |
| US-20190300500-A1 | PIPERIDINYL NOCICEPTIN RECEPTOR COMPOUNDS | OPRL1, OPRK1, OPRM1 | OPRM1 3/4885OPRL1 1/4885OPRK1 2/4885 |
| US-20180155314-A1 | PIPERDINYL NOCICEPTIN RECEPTOR COMPOUNDS | OPRL1, OPRK1, OPRD1 | OPRM1 4/4885OPRL1 1/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.